

4
RECEIVED
CENTRAL FAX CENTER

MAY 04 2006

OFFICIAL COMMUNICATION FACSIMILE

TO THE ATTENTION OF:

MAIL STOP AMENDMENT

CENTRAL FAX NO: 571-273-8300

Number of pages including this page 4 pages

Applicant : Beverly L. Davidson et al.	Art Unit : 1635
Serial No. : 10/522,954	Examiner : Unknown
Filed : January 31, 2005	Docket : 17023.045US2
Title : ALLELE-SPECIFIC SIRNA-MEDIATED GENE SILENCING	

MAIL STOP AMENDMENT


Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Attached to this facsimile communication cover sheet is a Transmittal Form, Information Disclosure Statement (1 pg.), Form 1449 (1 pg.) and copy of one (1) cited reference, faxed this 4th day of May, 2006, to the Central Fax Center, U.S. Patent and Trademark Office.

Respectfully submitted,


Peter L. Malen
Reg. No. 44,894

Date: May 4, 2006

Customer Number 53137

Viksnins Harris & Padys PLLP
PO Box 111098
St. Paul, MN 55111-1098
Telephone: (952) 876-4094
Facsimile: (952) 876-4098

NOTE: This facsimile is intended for the addressee only and may contain privileged or confidential information. If you have received this facsimile in error, please immediately call us collect at (952) 876-4091 to arrange for its return. Thank you.

BEST AVAILABLE COPY

May 4 2006

S/N 10/522,954PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Beverly L. Davidson et al.	Examiner:	Unknown
Serial No.:	10/522,954	Group Art Unit:	1635
Filed:	January 31, 2005	Docket:	17023.045US2
Title:	ALLEL-SPECIFIC SIRNA-MEDIATED GENE SILENCING		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. § 1.97, no fee or statement is required with the Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 503503 in order to have this Information Disclosure Statement considered. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,
 Beverly L. Davidson et al.
 By their Representatives,
 Viksnins Harris & Padys PLLP
 P.O. Box 111098
 St. Paul, MN 55111
 952 876-4094

Date May 04, 2006
 By Peter L. Malen
 Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8: I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 4 day of May, 2006.

Lynda Mae
 Name

Lynda Mae
 Signature

Substitute for form 1449A/PTO and/or 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)

Complete if Known

Application Number	10/522,954
Filing Date	January 31, 2005
First Named Inventor	Davidson
Group Art Unit	1635
Examiner Name	Unknown

Sheet 1 of 1

Attorney Docket No: 17023.045US2

US PATENT DOCUMENTS

Examiner Initials*	US Document Number	Publication Date	Name of Patentee/Applicant of Document

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include last name of the first author, "Title of the Article", "Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).
	Goto et al., "Suppression of Huntington Gene Expression by siRNA: A Possible Therapeutic Tool for Huntington's Disease", Neurology, 60(5), Suppl 1, page A286, Abstract P04.055 (2003).

AVAILABLE

EXAMINER**DATE CONSIDERED**

Substitute Information Disclosure Statement Form (PTO-1449)

* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 609. Date line through citation if not considered. Include copy of the form with next communication to Applicant.